Suppr超能文献

低 BMI(身体质量指数)会增加耐多药结核病患者的全因死亡率。

Low BMI increases all-cause mortality rates in patients with drug-resistant TB.

机构信息

National Center for Disease Control and Public Health, Tbilisi, Georgia.

Department of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, GA.

出版信息

Int J Tuberc Lung Dis. 2022 Apr 1;26(4):326-333. doi: 10.5588/ijtld.21.0450.

Abstract

Loss to follow-up (LTFU) is common among patients with drug-resistant TB (DR-TB) receiving second-line TB treatment; however, little is known about outcomes after LTFU, including mortality. To determine rates of and factors associated with all-cause mortality among patients with DR-TB who were LTFU. Retrospective cohort study of adult patients with DR-TB in Georgia who initiated second-line TB treatment during 2011-2014 and were LTFU. Survival analyses were used to estimate all-cause mortality rates and adjusted hazard ratios (aHR). During 2011-2014, 2,437 second-line treatment episodes occurred and 695 patients were LTFU. Among 695 LTFU patients, 143 (21%) died during 2,686 person-years (PY) post-LTFU (all-cause mortality rate 5.1%, 95% CI 4.3-6.0 per 100 PY). In multivariable analysis, low weight (BMI < 18.5 kg/m²) at treatment initiation (aHR 3.2, 95% CI 2.2-4.7), return to treatment after LTFU (aHR 3.1, 95% CI 2.2-4.4), <12 months of treatment (aHR 2.4, 95% CI 1.4-4.1) and a pre-LTFU positive culture (aHR 3.3, 95% CI 2.2-4.9) were associated with all-cause mortality. High all-cause mortality occurred among patients with DR-TB after LTFU despite a low HIV prevalence. Providing additional assistance for patients during DR-TB treatment to prevent LTFU and use of new and shorter treatment regimens may reduce mortality among LTFU.

摘要

失访(LTFU)在接受二线结核病(DR-TB)治疗的耐多药结核病(DR-TB)患者中很常见;然而,对于 LTFU 后的结局,包括死亡率,知之甚少。本研究旨在确定失访的耐多药结核病(DR-TB)患者的全因死亡率及其相关因素。

本研究是对 2011 年至 2014 年期间在格鲁吉亚接受二线结核病治疗并失访的成年 DR-TB 患者进行的回顾性队列研究。采用生存分析估计全因死亡率和调整后的危险比(aHR)。2011 年至 2014 年,共发生 2437 例二线治疗,695 例患者失访。在 695 例失访患者中,有 143 例(21%)在失访后 2686 人年(PY)内死亡(全因死亡率为 5.1%,95%CI 4.3-6.0/100 PY)。在多变量分析中,治疗开始时体重偏低(BMI<18.5kg/m²)(aHR 3.2,95%CI 2.2-4.7)、失访后重新开始治疗(aHR 3.1,95%CI 2.2-4.4)、治疗时间<12 个月(aHR 2.4,95%CI 1.4-4.1)和治疗前阳性培养(aHR 3.3,95%CI 2.2-4.9)与全因死亡率相关。尽管 HIV 患病率较低,但耐多药结核病(DR-TB)患者失访后仍有较高的全因死亡率。在 DR-TB 治疗期间为患者提供额外帮助以防止失访,并使用新的、更短的治疗方案,可能会降低失访患者的死亡率。

相似文献

10
Isoniazid mono-resistant tuberculosis: Time to take it seriously.异烟肼单耐药结核病:是时候认真对待了。
Indian J Tuberc. 2019 Apr;66(2):247-252. doi: 10.1016/j.ijtb.2019.04.001. Epub 2019 Apr 9.

引用本文的文献

本文引用的文献

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验